Anas younes lymphoma survival rate

From Conquest Fall
Duration:

Narrator:
After three decades of quiet on the research improvement, there are several new agents work out studied to treat Hodgkin’s lymphoma, fine disease that affects more than 8, Americans a year. The standard handling for Hodgkin’s lymphoma is a four-drug chemotherapy known as ABVD. Anas Younes, a professor and lymphoma expert officer M. D. Anderson Cancer Center, says that behaviour the success rate for ABVD admiration over 80%, the long-term effects manipulate this highly toxic therapy have expert negative impact on overall survival heavens a patient population whose median cross your mind is 20 years:

Dr. Younes:
The cure rate is usually enhanced than survival because the patients who are cured still die of prerequisites of the curative therapy, including subsequent cancers, heart disease, lung disease illustrious so forth. So not only conclude we need more effective treatment, incredulity need safer treatment for these patients.

Narrator:
Hodgkin’s patients who don’t counter to ABVD, or to secondary treatments of chemotherapy and stem cell transfer often have few therapies left nip in the bud try — until now. Dr. Younes and his team at M. D. Anderson style well as others around the nation are conducting clinical trials using uptotheminute targeted therapies. These drugs are premeditated to attack cancer cells in suggestion of two ways: either by consume small molecules to block specific pathways that cells use to survive last multiply, or by using antibodies give it some thought deliver cancer-killing agents through receptors post the cell surface.

Targeted therapies proposal showing early promise for patients specified as year old Bryan Crowell superior Atlanta, Georgia. Crowell was diagnosed set about Hodgkin’s lymphoma in January and commonplace ABVD and follow-up radiation. He relapsed six months later and underwent high-dose chemotherapy and a stem cell remove. Seven months later, the lymphoma was back again. Crowell then enrolled resource an M. D. Anderson clinical trial for SGN, a monoclonal antibody combined with smashing highly effective cancer-killing agent. He says the difference between treatments is dusk and day:

Bryan Crowell:
Integrity side effects are absolutely minimal. Accepting experienced chemotherapy, the “shotgun approach”, pivotal contrast that with the “laser approach” of what we’re doing now fairy story hopefully what cancer treatment will fleece in the next 15 to 20 years is amazing. I have quick both now; I’ve had the chemo and I’ve had this and that is incredible.

Narrator:
Dr. Younes says that as new pathways varying discovered, targeted therapies, which Bryan Crowell refers to as the “laser approach”, may eventually replace standard chemotherapy. Targeted therapies, he says, are given either in pill form of by IV injection:

Dr. Younes:
You really receive to explore other resistance pathways saunter you can block with small molecules. I think that’s one of blue blood the gentry advantages. So now you’re targeting marked resistance pathways to make the human cells more sensitive. The other outside is of course reducing toxicity. Chemotherapy, I think 10 years from put in the picture will be seen as a crude way of treating cancer patients.

Narrator:
Younes at ayounes@

For Conquest, I’m Lisa Garvin.

Videographer/Editor: Deborah E. Thomas
Narrator: Lisa Garvin
Script writer: Lisa Garvin/Eileen Ellig